长期口服孟鲁司特对轻、中度持续哮喘患者肺功能及过敏反应指标的影响  

Effect of long time oral montelukast on pulmonary function and allergy index of patients with slight and moderate asthma

作　　者：鲁慧敏[1] 杨玲[1] 施萍[1] 

机构地区：[1]上海交通大学医学院附属新华医院呼吸内科,200092

出　　处：《上海医学》2007年第9期669-671,共3页Shanghai Medical Journal

摘　　要：目的观察长期口服白三烯受体拮抗剂孟鲁司特对轻、中度持续哮喘患者肺功能及过敏反应指标的影响。方法比较60例轻、中度持续哮喘患者治疗前及口服孟鲁司特1周、2个月、6个月后的第一秒用力呼气量占用力肺活量百分率(FEV_1%)、最大呼气流量(PEF)、PEF昼夜波动率和症状记分,以及治疗前与治疗6个月后的过敏反应指标。结果与治疗前比较,治疗6个月后FEV_1%由(54.77±10.67)%增至(65.79±11.47)%,PEF由(4.32±1.57)L/min增至(5.48±1.48)L/min,PEF昼夜波动率由(13.22±8.92)%降至(5.32±3.78)%,症状记分由(1.98±0.71)分降至(1.24±0.54)分,差异均有统计学意义(P值均<0.01)。临床控制率为75.0%,显效率为13.3%,总有效率达88.3%。治疗6个月后,血尘螨特异性IgE、总IgE、嗜酸性粒细胞阳离子蛋白(ECP)和外周血嗜酸性粒细胞(EOS)计数均较治疗前明显降低(P值均<0.05)。结论长期口服孟鲁司特能明显改善轻、中度持续哮喘患者的症状、肺功能及过敏反应指标。Objective To investigate the effect of long time oral moutlukast on the pulmonary function and allergy index of patients with slight and moderate asthma. Methods The forced expiratory volume in one second to forced vital capacity ratio （FEV1%）, peak expiratory flow（PEF）, diurnal fluctuation rate of PEF, and the symptom scores were measured in 60 patients with slight and moderate asthma before and 1 week, 2 months, and 6 months after oral administration of moutlukast; the allergy indices of patients were compared before and 6 months after taking moutlukat. Results Before treatment, the mean values of FEV1%, PEF, diurnal fluctuation rate of PEF daywere（54.77±10.67）%, （4.32±1.57） L/min, and（13.22 ±8.92）%, respectively： after treatment, the numbers were（65.79 ± 11.47） % ,（5.48 ±1.48） L/min, and（5.23±3.78） % , respectively （all P 〈 0.01）. The symptom score decreased from 1.98 ± 0.71 to 1.24 ± 0.54（P〈0.01）. The clinical control rate of patients was 75.0 %, significantly effective rate of patients was 13.3 %, and the total effective rate was 88.3 %. After 6 months treatment, the patients＇ serum sIgE, total IgE, eosinophil cationic protein（ECP） and eosinophil differential count were all markedly decreased compared with those before treatment （all P 〈 0.05）. Conclusion Long time oral moutlukast can obviously improve the symptoms, lung function, and allergy index of patients with slight to moderate asthma.

关 键 词：白三烯受体拮抗剂 哮喘 肺功能 过敏 

分 类 号：R562.25[医药卫生—呼吸系统]